The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell linesLinn Reinholdt, Karen Dybkær, Maria Bach Laursen et al.|Biomarker Research|2016Cited by 31
High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patientsMaria Bach Laursen, Karen Dybkær, Ditte Starberg Jespersen et al.|Oncotarget|2019Cited by 28
High Expression of CXCR4 Impairs Anti-CD20 Monoclonal Antibody (Rituximab)-Dependent Cytotoxicity in Diffuse Large B-Cell LymphomaLinn Reinholdt, Karen Dybkær, Maria Bach Laursen et al.|Blood|2015Cited by 2
Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remissionJulie Støve Bødker, Hans Erik Johnsen, Marianne Tang Severinsen et al.|Experimental Hematology and Oncology|2017Cited by 2
Additional file 2: of The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell linesLinn Reinholdt, Karen Dybkær, Alexander Schmitz et al.|VBN Forskningsportal (Aalborg Universitet)|2016Cited by 0